Back to Search
Start Over
The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis
- Source :
- BMC Women's Health, BMC Women's Health, Vol 20, Iss 1, Pp 1-11 (2020)
- Publication Year :
- 2020
- Publisher :
- BioMed Central, 2020.
-
Abstract
- BackgroundTo investigate the efficacy of neoadjuvant chemotherapy (NCT), neoadjuvant endocrine therapy (NET) and neoadjuvant chemoendocrine therapy (NCET) on the tumour response, including pathological complete response (pCR) rate and overall response rate (ORR), in postmenopausal women with hormone receptor (HR)-positive breast cancer.MethodsBased on a PRISMA-IPD statement, the PubMed, Embase and Cochrane Library databases were used to identify eligible trials published from inception to 7 May 2019. Pooled odds ratio (OR) with 95% confidential interval (CI) was calculated to assess the pCR rate and ORR of tumours among those three treatments via fixed- or random-effect Mantel-Haenszel models in terms of a Heterogeneity Chi2test with a significant level ofp ResultsThe analysed data consisted of 10 eligible clinical trials with 971 unique HR-positive breast cancer patients. The pooled results indicated that the pCR rate of those patients undergoing NET was significantly lower than those undergoing NCT (pooled OR, 0.48; 95% CI, 0.26–0.90), whereas the difference of ORR between both therapies was not statistically significant (pooled OR, 1.05; 95% CI, 0.73–1.52). The combined paradigm of NCET compared with the monotherapy of NET or NCT did not present a significantly improved pCR rate or ORR (pooled OR, 2.61; 95% CI, 0.94–7.25; and 2.25; 95% CI, 0.39–13.05; respectively).ConclusionPostmenopausal HR-positive breast cancer patients after NCT may have better tumour response than those after NET, while those undergoing NCET may not manifest the apparently improved clinical efficacies compared to those receiving monotherapy.
- Subjects :
- Oncology
medicine.medical_specialty
Tumour response
Antineoplastic Agents, Hormonal
medicine.medical_treatment
Breast Neoplasms
Cochrane Library
lcsh:Gynecology and obstetrics
Neoadjuvant chemotherapy
Neoadjuvant chemoendocrine therapy
03 medical and health sciences
0302 clinical medicine
Breast cancer
Internal medicine
medicine
Humans
030212 general & internal medicine
Neoadjuvant therapy
lcsh:RG1-991
Aged
Chemotherapy
business.industry
lcsh:Public aspects of medicine
Obstetrics and Gynecology
lcsh:RA1-1270
General Medicine
Odds ratio
Neoadjuvant endocrine therapy
Middle Aged
medicine.disease
Neoadjuvant Therapy
Clinical trial
Postmenopause
Treatment Outcome
Reproductive Medicine
Receptors, Estrogen
Hormone receptor
Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
Meta-analysis
Female
business
Research Article
Subjects
Details
- Language :
- English
- ISSN :
- 14726874
- Volume :
- 20
- Database :
- OpenAIRE
- Journal :
- BMC Women's Health
- Accession number :
- edsair.doi.dedup.....c975f5da9008a3b2fc66872ba3d621c4